Drugs / pPJV7630
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00310271 | Apr → Dec 2006 | herpes simplex type 2 infectious disease | PowderMed | Completed | No outcome recorded |
| Phase 1 | NCT00274300 | Aug 2004 → Jul 2005 | genital herpes simplex type 2 infectious disorder | PowderMed | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pPJV7630 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00274300 ↗ |
| Modality | Vaccine | “pPJV7630 HSV-2 DNA vaccine” NCT00274300 ↗ |
| Route | Other | “administered by Particle Mediated Epidermal Delivery (PMED )” NCT00274300 ↗ |